However, JAKi ruxolitinib or momelotinib decreased the target cell in vitro killing capacity of B7-H3 CAR T cells, regardless of their co-culture with non-stressed or stressed tumor cells (Supplementary Fig. 9f). The gene discussed is CD276; the disease is neoplasm.